Our Advisors

David Loewenstein,
Ph.D., ABPP/CN,

University of Miami Miller School of Medicine

Dr. David Loewenstein is the Director of the Center for Cognitive Neuroscience and Aging (CNSA). and Professor of Psychiatry and Behavioral Sciences for the University of Miami School of Medicine. He is a board-certified clinical neuropsychologist and Director of the Division of Neuropsychology. Previously, Dr. Loewenstein served as Director of Neuropsychology Laboratories and Research at Mount Sinai Medical Center in Miami Beach, FL and Chief of Psychology for Jackson Memorial Hospital. He has been continuously funded by the National Institutes of Health at the University of Miami for more than 25 years and has brought in over 20 million dollars in Federal and State grants. His work is regularly published in top scientific journals and is considered cutting-edge. Dr. Loewenstein’s laboratory has a long history in the development of innovative cognitive and neuropsychological instruments.

Advisor

Dr. Loewenstein developed the first scale for the direct assessment of functional capacity in Alzheimer’s disease which has been translated into numerous languages. Most recently, Dr. Loewenstein and associates developed the Loewenstein and Acevedo Scales for Semantic Interference and Learning (LASSI-L), a cognitive stress test to address the concern that current neuropsychological measures may not capture the earliest stage of Alzheimer’s disease. The LASSI-L is a sensitive marker of the early manifestations of AD and has been increasingly adapted by other laboratories.

Advisor

Rosie E. Curiel Cid,
PsyD,

University of Miami Miller School of Medicine

Dr. Curiel Cid, is a Neuropsychologist and Associate Professor in the Department of Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine and Chief of Cross-Cultural Neuropsychology and Cognitive Neuroscience at the Center for Cognitive Neuroscience and Aging. Dr. Curiel Cid specializes in the early cognitive and functional assessment of neurodegenerative conditions, such as Alzheimer’s disease and related disorders. She is Principal Investigator of a longitudinal study funded by the National Institutes of Health/National Institute on Aging entitled: Precision-based Computerized Assessment for the Detection of MCI in Older Adults, and is an active Co-investigator on various state and federally funded studies related to aging and cognition including the 1Florida Alzheimer’s Disease Research Center.

Her program of research focuses on the development of novel and cross-culturally applicable cognitive assessment paradigms. She along with Dr. David Loewenstein and their team have generated promising data that these novel cognitive outcome measures are sensitive enough to detect subtle cognitive deficits specific to preclinical Alzheimer’s disease, and are highly associated with biological markers of early AD brain pathology including CSF markers, amyloid imaging and structural and functional neuroimaging. Dr. Curiel Cid’s work focuses on technologically enhancing these innovative cognitive paradigms into user-friendly clinical outcome measures with the goal of advancing cognitive assessment efforts in clinical trials targeting preclinical disease. She and her team have led the development of the brief computerized version of the renowned LASSI-L, a cognitive stress test that has shown sensitivity and specificity at detecting cognitive change in preclinical and prodromal Alzheimer’s disease.